Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.49 |
| ▸ | ARG2 | P78540 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360118 | 1.00 | ARG1 (0.49) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL30382824 | 0.98 | ARG1 (0.47) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4684924 | 0.98 | ARG1 (0.47) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Ethylene Glycol SCHEMBL28530734 | 0.95 | ARG1 (0.45) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| SCHEMBL21645480 | 0.93 | ARG1 (0.43) | ARG1ARG2PARP1MEN1ALDH1A1 | |
| SCHEMBL28516379 | 0.83 | ARG1 (0.37) | ARG1ARG2 | |
| SCHEMBL14265250 | 0.82 | ARG1 (0.54) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12764363 | 0.81 | ARG1 (0.36) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| SCHEMBL8190743 | 0.81 | ARG1 (0.36) | ARG1ARG2PARP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1359302 | 0.80 | ARG1 (0.35) | ARG1ARG2PARP1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760881-B1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | NOSOPHARM (FR) | 2017-11-01 | — | — | EP | claimed |
| US-9260481-B2 | Peptide derivatives as antibiotics | NOSOPHARM (FR) | 2016-02-16 | — | — | US | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-20150175659-A1 | Peptide Derivatives as Antibiotics | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2015-06-25 | — | — | US | claimed |
| EP-2760881-A1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | Nosopharm (FR) | 2014-08-06 | — | — | EP | claimed |
| WO-2013045600-A1 | NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS | NOSOPHARM (FR) | 2013-04-04 | — | — | WO | claimed |
| US-20110118239-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4]NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | TARGACEPT, INC. (US) | 2011-05-19 | — | — | US | claimed |
| JP-2011509933-A | — | — | 2011-03-31 | — | — | JP | claimed |
| EP-2242364-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIROÝ4.4¨NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | Targacept Inc. (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009091561-A1 | PREPARATION AND ENANTIOMERIC SEPARATION OF 7-(3-PYRIDINYL)-1,7-DIAZASPIRO[4.4] NONANE AND NOVEL SALT FORMS OF THE RACEMATE AND ENANTIOMERS | TARGACEPT, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| US-20060136023-A1 | Method and apparatus for patient temperature control employing administration of anti-shivering agents | MARVIN, ROBERT | 2006-06-22 | — | — | US | claimed |
| US-6869440-B2 | Method and apparatus for patient temperature control employing administration of anti-shivering agents | INNERCOOL THERAPIES, INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20030060863-A1 | Method and apparatus for patient temperature control employing administration of anti-shivering agents | ZOLL CIRCULATION, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2003015672-A1 | METHOD AND APPARATUS FOR PATIENT TEMPERATURE CONTROL EMPLOYING ADMINISTRATION OF ANTI-SHIVERING | INNERCOOL THERAPIES, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| CN-122055379-A | Compounds containing one or more diboronate esters and related insulin analogues | 普罗托莫科技公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2003013344-A2 | METHOD AND DEVICE FOR PATIENT TEMPERATURE CONTROL EMPLOYING OPTIMIZED REWARMING | INNERCOOL THERAPIES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20030023288-A1 | Method and device for patient temperature control employing optimized rewarming | ZOLL CIRCULATION, INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002094856-A2 | GPE ANALOGS AND PEPTIDOMIMETICS | NEURONZ LIMITED (NZ) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | ARG1 2202/4885ARG2 2799/4885PARP1 3931/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | ARG1 415/4885ARG2 478/4885PARP1 4242/4885 |
| US-20150175659-A1 | Peptide Derivatives as Antibiotics | VIP, NGLY1, NRDC | ARG1 274/4885ARG2 826/4885PARP1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.